IBio And AstralBio Say They 'Have Identified a Molecule With Therapeutic Potential for Treating Muscle Wasting and Obesity, Which Is Designed for Subcutaneous Administration and Has Potential for an Extended Half-life'; Are Working On Plans To Advance...

BenzingaOct 10 20:06

Express News | Ibio Inc - Has Exclusive Option to License Three Cardiometabolic Targets From Astralbio

BreakingsOct 10 20:02

Express News | Ibio Inc - Aims to File Ind Application for Myostatin Program by End of 2025

BreakingsOct 10 20:01

Express News | Ibio Inc - Plans Non-Cgmp in Vivo Studies With Early 2025 Readouts

BreakingsOct 10 20:01

Express News | Ibio and Astralbio Provide Update on Myostatin Program for Obesity

BreakingsOct 10 20:00

IBio and AstralBio Provide Update on Myostatin Program for Obesity

GlobeNewswireOct 10 20:00